BioSpace News Archive

ABCAM PLC: New PBS-Only Antibodies Enable More Flexible Research

Abcam’s new phosphate buffered saline (PBS)-only recombinant antibodies are free from preservatives and stabilising agents, offering improved flexibility for researchers conducting more complex experiments.

October 11, 2018
·
2 min read
Drug Development

NIH’s Undiagnosed Diseases Network Identifies 31 New Syndromes

Examples of new syndromes include hypotonia, ataxia, and delayed development syndrome (HADDS) and Sashi-Pena syndrome (SHAPNS).

October 11, 2018
·
3 min read
·
Mark Terry
Business

Chinese Pharma Companies Continue to Shake Hands With Western Partners

Brii Biosciences is one of many China-based companies that are heavily investing in U.S. biotech and pharmaceutical companies to support the development of programs that could come back to China for approval.

October 11, 2018
·
3 min read
·
Alex Keown
Genetown

Wave Life Sciences to Develop Programs in Rare, Genetic Eye Diseases

Research will focus on inherited retinal diseases associated with RHO, USH2A, ABCA4 and CEP290

October 11, 2018
·
5 min read
Genetown

TESARO Announces Data Presentations at the ESMO 2018 Congress

TESARO, Inc. today announced that data from six abstracts will be presented at the European Society for Medical Oncology (ESMO) Congress from October 19-23, 2018 in Munich, Germany.

October 11, 2018
·
5 min read
Deals

Focused on Off-The-Shelf CAR-T, Allogene Therapeutics Hits the Nasdaq at $18 per Share

Allogene Therapeutics began trading on the Nasdaq Stock Exchange today under the ALLO ticker. The price was at the top of its range, $18 per share. The company plans to raise $288 million with the sale of about 16 million shares.

October 11, 2018
·
3 min read
·
Mark Terry
Policy

Trump Signs FTC Law That Allows for Biosimilar Scrutiny

President Donald Trump signed a bill into law yesterday that requires pharmaceutical companies to provide details of biosimilar deals to the Federal Trade Commission (FTC) for antitrust scrutiny.

October 11, 2018
·
3 min read
·
Mark Terry
Drug Development

BioPharmX Initiates Phase 2b Trial of BPX-04 for Rosacea

Trial will evaluate 1% concentration of minocycline carried by company’s patented HyantX™ delivery system

October 11, 2018
·
4 min read
Policy

AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Sandoz

AbbVie announced today a global resolution of all intellectual property-related litigation with Sandoz over its proposed biosimilar adalimumab product.

October 11, 2018
·
3 min read
Business

TOHealth! Announces New Co-Chairs and Launch of the Updated Brand

TOHealth!, a not-for–profit platform to bring together and promote the Toronto Region Health Cluster as a global health innovation hub, is excited to announce Allan Miranda, Head of JLABS Canada and Scott Kaplanis, Partner at Epic Capital Management as the new Co-Chairs.

October 11, 2018
·
2 min read